- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00112658
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective as first-line therapy in treating pancreatic cancer.
PURPOSE: This randomized phase II/III trial is studying how well combination chemotherapy works as first-line therapy in treating patients with metastatic pancreatic cancer.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
OBJECTIVES:
Primary
- Compare the objective response rate in patients with metastatic adenocarcinoma of the pancreas treated with oxaliplatin, irinotecan, leucovorin calcium, and fluorouracil vs gemcitabine as first-line chemotherapy. (Phase II)
- Compare the survival of patients treated with these regimens. (Phase III)
Secondary
- Compare the toxicity of these regimens in these patients.
- Compare progression-free survival of patients treated with these regimens. (Phase III)
- Compare the overall response rate in patients treated with these regimens. (Phase III)
- Compare quality of life of patients treated with these regimens. (Phase III)
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oxaliplatin IV over 2 hours, irinotecan IV over 1½ hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days.
- Arm II: Patients receive gemcitabine IV on days 1, 8, 15, 22, 29, 36, and 43. Beginning on day 57, patients receive gemcitabine IV once weekly for 3 weeks (days 57, 64, and 71). Courses repeat every 28 days.
PROJECTED ACCRUAL: A total of 348 patients (88 for phase II and 260 for phase III) will be accrued for this study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Amiens, Frankrig, 80054
- Centre Hospitalier Universitaire d'Amiens
-
Avignon, Frankrig, 84902
- Hopital Duffaut
-
Belfort, Frankrig, 90000
- Centre Hospitalier General
-
Besancon, Frankrig, 25030
- Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
-
Bobigny, Frankrig, 93009
- Hôpital Avicenne
-
Bordeaux, Frankrig, 33076
- Institut Bergonie
-
Bordeaux, Frankrig, 33075
- Hopital Saint André
-
Bordeaux, Frankrig, 33300
- Polyclinique Bordeaux Nord Aquitaine
-
Boulogne Sur Mer, Frankrig, 62200
- Centre Hospitalier Docteur Duchenne
-
Boulogne-Billancourt, Frankrig, F-92104
- Hopital Ambroise Pare
-
Caen, Frankrig, 14076
- Centre Regional Francois Baclesse
-
Caen, Frankrig, 14033
- CHU de Caen
-
Clermont-Ferrand, Frankrig, 63011
- Centre Jean Perrin
-
Clermont-Ferrand, Frankrig, 63058
- CHR Clermont Ferrand, Hotel Dieu
-
Colmar, Frankrig, 68024
- Hôpitaux civils de Colmar
-
Creteil, Frankrig, 94000
- Centre Hospitalier Universitaire Henri Mondor
-
Dijon, Frankrig, 21034
- Hopital Du Bocage
-
Dijon, Frankrig, 21079
- Centre de Lutte Contre le Cancer Georges-Francois Leclerc
-
Elbeuf, Frankrig, 76503
- Centre Hospitalier Intercommunal St. Aubin les Elbeuf
-
Epernay, Frankrig, 51200
- Clinique Saint Vincent
-
La Roche Sur Yon, Frankrig, F-85025
- Centre Hospitalier departemental
-
Le Havre, Frankrig, 76600
- CMC Les Ormeaux
-
Lille, Frankrig, 59020
- Centre Oscar Lambret
-
Lille, Frankrig, F-59020
- Hopital Saint Vincent de Paul
-
Lormont, Frankrig, 33310
- Polyclinique des Quatre Pavillons
-
Lyon, Frankrig, 69437
- Hopital Edouard Herriot - Lyon
-
Lyon, Frankrig, 69373
- Centre Leon Berard
-
Lyon, Frankrig, 69317
- Hôpital de La Croix Rousse
-
Marseille, Frankrig, 13385
- CHU de la Timone
-
Marseille, Frankrig, 13915
- CHU Nord
-
Marseille, Frankrig, 13291
- Hopital Ambroise Pare
-
Metz, Frankrig, 57038
- Hopital Notre-Dame de Bon Secours
-
Mont-de-Marsan, Frankrig, 40000
- Centre Hospitalier General de Mont de Marsan
-
Montpellier, Frankrig, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nantes-Saint Herblain, Frankrig, 44805
- Centre Regional Rene Gauducheau
-
Orleans, Frankrig, 45067
- CHR D'Orleans - Hopital de la Source
-
Paris, Frankrig, 75018
- Hôpital Bichat - Claude Bernard
-
Paris, Frankrig, 75674
- Hopital Saint Michel
-
Perpignan, Frankrig, 66046
- Centre Hospitalier de Perpignan
-
Pierre Benite, Frankrig, 69495
- Centre Hospitalier Lyon Sud
-
Reims, Frankrig, 51092
- CHU - Robert Debre
-
Reims, Frankrig, 51056
- Institut Jean Godinot
-
Rennes, Frankrig, 35064
- Centre Eugene Marquis
-
Rouen, Frankrig, 76031
- Hopital Charles Nicolle
-
Saint Brieuc, Frankrig, F-22015
- Clinique Armoricaine de Radiologie
-
Saint Cloud, Frankrig, 92210
- Centre René Huguenin
-
Sainte Foy Les Lyon, Frankrig, 69110
- Clinique Charcot
-
Semur en Auxois, Frankrig, 21140
- Centre Hospitalier de Semur en Auxois
-
Strasbourg, Frankrig, 67098
- Hopital Universitaire Hautepierre
-
Strasbourg, Frankrig, 67065
- Centre Paul Strauss
-
Tarbes, Frankrig, 65013
- Centre hospitalier de Tarbes
-
Toulouse, Frankrig, 31052
- Institut Claudius Régaud
-
Tours, Frankrig, 37044
- CHU de Tours
-
Vandoeuvre-les-Nancy, Frankrig, 54511
- Centre Alexis Vautrin
-
Villejuif, Frankrig, F-94805
- Institut Gustave Roussy
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed adenocarcinoma of the pancreas
No other pancreatic tumor type, including either of the following:
- Neuroendocrine tumor
- Acinar cell tumor
- Metastatic disease
- Measurable disease in an area not previously irradiated
- No cerebral metastases or meningeal involvement of the tumor
PATIENT CHARACTERISTICS:
Age
- 18 to 75
Performance status
- WHO 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (biliary drainage allowed)
Renal
- Creatinine < 120 mmol/L
Cardiovascular
- No prior myocardial infarction
- No prior angina
- No uncompensated cardiac or coronary insufficiency
- No symptomatic arrhythmia
Gastrointestinal
- No prior inflammatory bowel disease
- No prior chronic diarrhea
- No unresolved symptomatic occlusion or subocclusion of the bowel
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No ongoing active infection
- No other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No contraindication to study treatment
- No other serious medical disorder that would preclude study treatment
- No psychiatric disorder or social or geographic situation that would preclude study participation
- Not detained or under the guardianship of another person
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy
Surgery
- Not specified
Other
- No concurrent participation in another clinical trial using therapeutic experimental agents
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Gemcitabin
|
|
Eksperimentel: Folfirinox
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
Objective response rate (Phase II)
|
Survival (Phase III)
|
Sekundære resultatmål
Resultatmål |
---|
Toksicitet
|
Progression-free survival (Phase III)
|
Quality of life (Phase III)
|
Overall response rate (Phase III)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Thierry Conroy, MD, Centre Alexis Vautrin
Publikationer og nyttige links
Generelle publikationer
- Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
- Ychou M, Desseigne F, Guimbaud R, et al.: Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): first results of the ACCORD 11 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4516, 2007.
- Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017 Sep 20;12(9):e0183288. doi: 10.1371/journal.pone.0183288. eCollection 2017.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Sygdomme i det endokrine system
- Neoplasmer i fordøjelsessystemet
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Bugspytkirtel neoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Enzymhæmmere
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Beskyttelsesagenter
- Topoisomerasehæmmere
- Mikronæringsstoffer
- Vitaminer
- Calciumregulerende hormoner og midler
- Topoisomerase I-hæmmere
- Modgift
- Vitamin B kompleks
- Gemcitabin
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Irinotecan
- Kalk
- Levoleucovorin
Andre undersøgelses-id-numre
- CDR0000430100
- FRE-FNCLCC-ACCORD-11/0402
- EU-20512
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kræft i bugspytkirtlen
-
Richard HungerMedizinische Hochschule Brandenburg Theodor FontaneAfsluttetVolume-Outcome Relation i Pancreatic Surgery
-
Tianjin Medical University Cancer Institute and...Ikke rekrutterer endnuPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForenede Stater
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Washington University School of MedicineUniversity of Oklahoma Medical Center; Northwestern University Chicago... og andre samarbejdspartnereAfsluttet
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaHolland
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbejdspartnereRekrutteringKræft i bugspytkirtlen | PDAC - Pancreatic Ductal AdenocarcinomaDet Forenede Kongerige
-
Andrei IagaruIkke længere tilgængeligCarcinoide tumorer | Islet Cell (Pancreatic NET) | Andre neuroendokrine tumorerForenede Stater
Kliniske forsøg med fluorouracil
-
CStone PharmaceuticalsAktiv, ikke rekrutterendeIkke-operabelt lokalt avanceret, tilbagevendende eller metastatisk spiserørspladecellecarcinomKina
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital... og andre samarbejdspartnereUkendtNasopharyngealt karcinomKina
-
Sun Yat-sen UniversityUkendt
-
Actavis Inc.AfsluttetAktinisk keratoseForenede Stater
-
The Netherlands Cancer InstituteAfsluttet
-
The Netherlands Cancer InstituteAfsluttet
-
Hokkaido Gastrointestinal Cancer Study GroupHokkaido University HospitalAfsluttet
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedThe Hong Kong Anti-Cancer Society; hong Kong Cancer FundAfsluttet
-
The Cleveland ClinicNational Cancer Institute (NCI)AfsluttetAktinisk keratose | Organ- eller vævstransplantation; KomplikationerForenede Stater
-
Boston UniversityRekrutteringOverfladisk basalcellekarcinom | Planocellulært karcinom in situForenede Stater